A phase 1b/2, safety lead-in and dose-expansion trial of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.

Authors: James J. Harding, Anthony El-Khoueiry, Makoto Ueno, Hong Jae Chon, Jin Won Kim, Hye Jin Choi, Myung Ah Lee, Valentine Barboux, Camelia Gliser, Nicole McNeer, Do-Youn Oh

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4219

Source: Full article

---

Abstract

TPS4219